Author of the publication

A randomized study of how physicians interpret research funding disclosures.

, , , , , , , , and . The New England journal of medicine, 367 (12): 1119-27 (September 2012)6941<m:linebreak></m:linebreak>GR: 2R25CA092203-08/CA/NCI NIH HHS/United States; GR: K08HS18465-01/HS/AHRQ HHS/United States; JID: 0255562; CIN: N Engl J Med. 2012 Sep 20;367(12):1152-3. PMID: 22992081; ppublish;<m:linebreak></m:linebreak>Publicació; Interpretació de resultats; Indústria; RCT.
DOI: 10.1056/NEJMsa1202397

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature., , and . Health affairs (Project Hope), 29 (10): 1842-8 (October 2010)CER; Recerca clínica; Introductori.Innovative research methods for studying treatments for rare diseases : methodological review, , and . British Medical Journal, 349 (nov24 15): g6802-g6802 (November 2014)Tipus d'estudis; RCT; Observacionals; Estudi petit; Dissenys adaptatius.Medical students' exposure to and attitudes about the pharmaceutical industry: a systematic review., , and . PLoS medicine, 8 (5): e1001037 (May 2011)6165<m:linebreak></m:linebreak>M3: doi:10.1371/journal.pmed.1001037;.A randomized study of how physicians interpret research funding disclosures., , , , , , , , and . The New England journal of medicine, 367 (12): 1119-27 (September 2012)6941<m:linebreak></m:linebreak>GR: 2R25CA092203-08/CA/NCI NIH HHS/United States; GR: K08HS18465-01/HS/AHRQ HHS/United States; JID: 0255562; CIN: N Engl J Med. 2012 Sep 20;367(12):1152-3. PMID: 22992081; ppublish;<m:linebreak></m:linebreak>Publicació; Interpretació de resultats; Indústria; RCT.Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval, , and . (2024)Changes in the Number of Continuation Patents on Drugs Approved by the FDA, , , and . 330 (5): 469 (2023)